

Ausgabe: face 3/2016
Thema: Zink als Therapieoption bei Acne vulgaris
Autor: Christian Nork

Literatur

1. Rzany B et al. Epidemiology of acne vulgaris. *J Dtsch Dermatol Ges.* 2006 Jan;4(1):8-9; Ghodsi SZ et al. Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study. *J Invest Dermatol.* 2009 Sep;129(9):2136-41.
2. Deutsche Dermatologische Gesellschaft. Behandlung der Akne. S2k - Leitlinie zur Therapie Akne. Korrigierte Fassung von 10/2011. AWMF-Register Nr. 013/017.
3. Franzke N et al. Quality of medical care of patients with acne vulgaris in Germany-- nationwide survey of pharmacy clients. *J Dtsch Dermatol Ges.* 2009 Dec;7(12):1060-3.
4. Mallon E et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. *Br J Dermatol.* 1999 Apr;140(4):672-6; Tan JK. Psychosocial impact of acne vulgaris: evaluating the evidence. *Skin Therapy Lett.* 2004 Aug-Sep;9(7):1-3, 9; Dalgard F et al. Self-esteem and body satisfaction among late adolescents with acne: results from a population survey. *J Am Acad Dermatol.* 2008 Nov;59(5):746-51.
5. Ozuguz P et al. Evaluation of serum vitamins A and E and zinc levels according to the severity of acne vulgaris. *Cutan Ocul Toxicol.* 2014 Jun;33(2):99-102.
6. Rostami Mogaddam M et al. Correlation between the severity and type of acne lesions with serum zinc levels in patients with acne vulgaris. *Biomed Res Int.* 2014;2014:474108.
7. Michaëlsson G et al. Effects of oral zinc and vitamin A in acne. *Arch Dermatol.* 1977 Jan;113(1):31-6.
8. Dreno B et al. Low doses of zinc gluconate for inflammatory acne. *Acta Derm Venereol.* 1989;69(6):541-3.
9. Dreno B et al. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. *Dermatology.* 2001;203(2):135-40.
10. Michaëlsson G et al. A double-blind study of the effect of zinc and oxytetracycline in acne vulgaris. *Br J Dermatol.* 1977 Nov;97(5):561-6.
11. Dreno B et al. Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. *Eur J Dermatol.* 2005 May-Jun;15(3):152-5.
12. Sardana K et al. Antibiotic resistance to Propionobacterium acnes: worldwide scenario, diagnosis and management. *Expert Rev Anti Infect Ther.* 2015 Jul;13(7):883-96.

13. Bae YS et al. Innovative uses for zinc in dermatology. *Dermatol Clin.* 2010 Jul;28(3):587-97; Poiraud C et al. Zinc gluconate is an agonist of peroxisome proliferator-activated receptor- α in the epidermis. *Exp Dermatol.* 2012 May;21(5):347-51.

14. Nationale Verzehrsstudie II, Ergebnisbericht Teil II, hrsg. vom Max Rubner-Institut, Bundesforschungsinstitut für Ernährung und Lebensmittel, Karlsruhe 2008.